These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Fyn: a novel molecular target in cancer. Saito YD; Jensen AR; Salgia R; Posadas EM Cancer; 2010 Apr; 116(7):1629-37. PubMed ID: 20151426 [TBL] [Abstract][Full Text] [Related]
6. The inhibition of SRC family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion. Je DW; O YM; Ji YG; Cho Y; Lee DH Pancreas; 2014 Jul; 43(5):768-76. PubMed ID: 24763074 [TBL] [Abstract][Full Text] [Related]
7. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Lu KV; Zhu S; Cvrljevic A; Huang TT; Sarkaria S; Ahkavan D; Dang J; Dinca EB; Plaisier SB; Oderberg I; Lee Y; Chen Z; Caldwell JS; Xie Y; Loo JA; Seligson D; Chakravari A; Lee FY; Weinmann R; Cloughesy TF; Nelson SF; Bergers G; Graeber T; Furnari FB; James CD; Cavenee WK; Johns TG; Mischel PS Cancer Res; 2009 Sep; 69(17):6889-98. PubMed ID: 19690143 [TBL] [Abstract][Full Text] [Related]
8. Src family kinases are required for integrin but not PDGFR signal transduction. Klinghoffer RA; Sachsenmaier C; Cooper JA; Soriano P EMBO J; 1999 May; 18(9):2459-71. PubMed ID: 10228160 [TBL] [Abstract][Full Text] [Related]
9. Srcasm corrects Fyn-induced epidermal hyperplasia by kinase down-regulation. Li W; Marshall C; Mei L; Gelfand J; Seykora JT J Biol Chem; 2007 Jan; 282(2):1161-9. PubMed ID: 17046829 [TBL] [Abstract][Full Text] [Related]
10. FYN promotes breast cancer progression through epithelial-mesenchymal transition. Xie YG; Yu Y; Hou LK; Wang X; Zhang B; Cao XC Oncol Rep; 2016 Aug; 36(2):1000-6. PubMed ID: 27349276 [TBL] [Abstract][Full Text] [Related]
11. Fyn is an important molecule in cancer pathogenesis and drug resistance. Elias D; Ditzel HJ Pharmacol Res; 2015 Oct; 100():250-4. PubMed ID: 26305432 [TBL] [Abstract][Full Text] [Related]
12. FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia. Chougule RA; Kazi JU; Rönnstrand L Oncotarget; 2016 Mar; 7(9):9964-74. PubMed ID: 26848862 [TBL] [Abstract][Full Text] [Related]
13. Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells. Eguchi R; Kubo S; Takeda H; Ohta T; Tabata C; Ogawa H; Nakano T; Fujimori Y Carcinogenesis; 2012 May; 33(5):969-75. PubMed ID: 22354875 [TBL] [Abstract][Full Text] [Related]
14. Distinct roles for N-Cadherin linked c-Src and fyn kinases in lens development. Leonard M; Zhang L; Bleaken BM; Menko AS Dev Dyn; 2013 May; 242(5):469-84. PubMed ID: 23361870 [TBL] [Abstract][Full Text] [Related]
15. Differential transformation capacity of Src family kinases during the initiation of prostate cancer. Cai H; Smith DA; Memarzadeh S; Lowell CA; Cooper JA; Witte ON Proc Natl Acad Sci U S A; 2011 Apr; 108(16):6579-84. PubMed ID: 21464326 [TBL] [Abstract][Full Text] [Related]
16. Upregulation of Tyrosine Kinase FYN in Human Thyroid Carcinoma: Role in Modulating Tumor Cell Proliferation, Invasion, and Migration. Zheng J; Li H; Xu D; Zhu H Cancer Biother Radiopharm; 2017 Nov; 32(9):320-326. PubMed ID: 29140740 [TBL] [Abstract][Full Text] [Related]
17. Identification and activation of Src family kinases in primary megakaryocytes. Lannutti BJ; Shim MH; Blake N; Reems JA; Drachman JG Exp Hematol; 2003 Dec; 31(12):1268-74. PubMed ID: 14662334 [TBL] [Abstract][Full Text] [Related]
18. Role of Fyn in hematological malignancies. Li S; Liu C; Tang Y J Cancer Res Clin Oncol; 2023 Aug; 149(9):6759-6767. PubMed ID: 36754870 [TBL] [Abstract][Full Text] [Related]
19. Src kinases as therapeutic targets for cancer. Kim LC; Song L; Haura EB Nat Rev Clin Oncol; 2009 Oct; 6(10):587-95. PubMed ID: 19787002 [TBL] [Abstract][Full Text] [Related]
20. SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer. Gururajan M; Cavassani KA; Sievert M; Duan P; Lichterman J; Huang JM; Smith B; You S; Nandana S; Chu GC; Mink S; Josson S; Liu C; Morello M; Jones LW; Kim J; Freeman MR; Bhowmick N; Zhau HE; Chung LW; Posadas EM Oncotarget; 2015 Dec; 6(42):44072-83. PubMed ID: 26624980 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]